• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.

作者信息

Alexandrescu Doru T, McClure Rebecca, Farzanmehr Haleh, Dasanu Constantin A

出版信息

J Clin Oncol. 2008 Aug 20;26(24):4047-8. doi: 10.1200/JCO.2008.18.3525.

DOI:10.1200/JCO.2008.18.3525
PMID:18711201
Abstract
摘要

相似文献

1
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.酪氨酸激酶抑制剂舒尼替尼和索拉非尼引起的继发性红细胞增多症。
J Clin Oncol. 2008 Aug 20;26(24):4047-8. doi: 10.1200/JCO.2008.18.3525.
2
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.接受多靶点激酶抑制剂索拉非尼和舒尼替尼治疗的患者的皮肤不良反应。
Br J Dermatol. 2009 Nov;161(5):1045-51. doi: 10.1111/j.1365-2133.2009.09290.x. Epub 2009 May 5.
3
Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.酪氨酸激酶抑制剂（舒尼替尼、索拉非尼和阿昔替尼）治疗转移性肾细胞癌患者的甲状腺功能障碍。
Jpn J Clin Oncol. 2012 Aug;42(8):742-7. doi: 10.1093/jjco/hys076. Epub 2012 May 23.
4
A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.一名肾癌患者使用两种不同的多靶点酪氨酸激酶抑制剂后发生急性溶血的病例。
Bull Soc Sci Med Grand Duche Luxemb. 2009(1):7-9.
5
[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].德国多靶点酪氨酸激酶抑制剂获批上市后转移性肾细胞癌的医学治疗
Aktuelle Urol. 2009 Jan;40(1):31-6. doi: 10.1055/s-2008-1038176. Epub 2009 Jan 28.
6
Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.晚期肾细胞癌中的酪氨酸激酶抑制剂：不断演变的治疗模式。
Clin Genitourin Cancer. 2009 Jan;7(1):9-10. doi: 10.3816/CGC.2009.n.001.
7
Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.舒尼替尼和索拉非尼序贯治疗转移性肝细胞癌。
Invest New Drugs. 2012 Aug;30(4):1768-72. doi: 10.1007/s10637-011-9707-4. Epub 2011 Jul 1.
8
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.接受多激酶抑制剂索拉非尼和舒尼替尼治疗的癌症患者的手足皮肤反应。
Ann Oncol. 2008 Nov;19(11):1955-61. doi: 10.1093/annonc/mdn389. Epub 2008 Jun 10.
9
Kidney cancer: Does hypothyroidism predict clinical outcome?肾癌：甲状腺功能减退症能否预测临床结局？
Nat Rev Urol. 2011 Jan;8(1):10-1. doi: 10.1038/nrurol.2010.191. Epub 2010 Nov 30.
10
[New drugs; sunitinib and sorafenib].[新药；舒尼替尼和索拉非尼]
Ned Tijdschr Geneeskd. 2007 Dec 29;151(52):2888-90.

引用本文的文献

1
Diagnosis, management, and outcomes of drug-induced erythrocytosis: a systematic review.药物性红细胞增多症的诊断、管理及预后：一项系统综述
Blood Adv. 2025 May 13;9(9):2108-2118. doi: 10.1182/bloodadvances.2024015410.
2
Regorafenib-related erythrocytosis in metastatic extra-gastrointestinal stromal tumor: a case report.瑞戈非尼相关的转移性胃肠外间质瘤红细胞增多症：一例报告
Front Oncol. 2024 Aug 6;14:1398055. doi: 10.3389/fonc.2024.1398055. eCollection 2024.
3
The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study.
平均红细胞体积和红细胞分布宽度在接受酪氨酸激酶抑制剂治疗的转移性肾细胞癌患者中的作用：MARECAP回顾性研究
Ther Adv Urol. 2023 Jul 22;15:17562872231187216. doi: 10.1177/17562872231187216. eCollection 2023 Jan-Dec.
4
Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma.在晚期肝细胞癌患者中，仑伐替尼治疗下的进行性红细胞增多症。
Cancer Chemother Pharmacol. 2023 Apr;91(4):337-344. doi: 10.1007/s00280-023-04519-6. Epub 2023 Mar 24.
5
Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study.索坦治疗的肾细胞癌患者血小板特性的定量和定性变化与循环索坦水平的关系：一项概念验证研究。
BMC Cancer. 2022 Jun 13;22(1):653. doi: 10.1186/s12885-022-09676-0.
6
Acute Lower Extremity Arterial Thrombosis Associated with Osimertinib-Induced Erythrocytosis.奥希替尼引起的红细胞增多症相关急性下肢动脉血栓形成。
Am J Case Rep. 2021 Sep 7;22:e932252. doi: 10.12659/AJCR.932252.
7
VEGFR-TKIs combined with chemotherapy for advanced non-small cell lung cancer: A systematic review.VEGFR酪氨酸激酶抑制剂联合化疗治疗晚期非小细胞肺癌：一项系统评价。
J Cancer. 2019 Jan 30;10(4):799-809. doi: 10.7150/jca.29643. eCollection 2019.
8
Case: Secondary polycythemia due to pazopanib in patients with metastatic renal cell carcinoma.病例：转移性肾细胞癌患者因帕唑帕尼导致的继发性红细胞增多症。
Can Urol Assoc J. 2017 Nov;11(11):E449-E450. doi: 10.5489/cuaj.4519.
9
Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies.肝细胞癌的靶向治疗与个性化医疗：耐药性、机制及治疗策略
J Hepatocell Carcinoma. 2017 Jul 11;4:93-103. doi: 10.2147/JHC.S106529. eCollection 2017.
10
Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study.阿昔替尼治疗转移性肾细胞癌期间血红蛋白水平升高作为疗效生物标志物：一项回顾性研究
BMC Cancer. 2017 May 22;17(1):355. doi: 10.1186/s12885-017-3312-7.